Moss Genomics Inc. is a biotechnology company specializing in genomics and microbiome research to provide advanced genetic insights in Canada. While it boasts a strong liquidity position with a current ratio of 4.54 and minimal debt, its financial health is concerning due to a negative return on equity of -72.2% and return on assets of -56.5%. The low market cap of $951.22K and stagnant share price at $0.01 suggest potential undervaluation, but the significant losses raise questions about sustainability and growth prospects.
Loading financial metrics...
Company has $55K in cash but burned $78K last quarter. At this burn rate, only 0.7 quarters of runway remain without additional financing.
Company posted a loss of $-676K over the last year, representing Infinity% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $311K over the last year.
Fortress balance sheet: cash covers total debt 11×, providing significant financial flexibility.
Excellent liquidity with current ratio of 4.5x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Health Information Services companies of a similar size
Based on 2025-FY (June 30, 2025)